LifeMD partners with Halozyme for exclusive telehealth co-marketing of XYOSTED, launching July 2026 in 37 states

LifeMD, Inc.

LifeMD will be the exclusive telehealth co-marketing partner for XYOSTED (testosterone enanthate) self-pay program.
Program launches July 2026; initially available in 37 states with a transparent $249/month all-inclusive price.
LifeMD's affiliated medical group will evaluate patients, and its pharmacy will be the preferred dispensing pharmacy.
Three-year initial term with automatic renewal; either party can terminate if co-marketing budget missed for two consecutive quarters.
Companies will jointly invest in consumer education and promotional initiatives to expand awareness of hypogonadism.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.